SCOTTSDALE, Ariz. -- With the annual flu season almost upon us, many government officials, both domestic and international, are concerned that SARS (Severe Acute Respiratory Syndrome) will make a comeback and become more widespread than the original epidemic. On Sept. 8, an ethnic Chinese Singapore citizen tested positive for SARS, further concerning officials of a resurgence of the disease. According to the World Health Organization (WHO), there had been over 8,400 SARS cases reported to date, with over 900 deaths.
In an attempt to assist local, federal and international officials deal with the possible threat of another outbreak, ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., has recently completed testing on the Hong Kong influenza virus, which is similar in nature to that of SARS. Company executives believe this research may indicate efficacy of their proprietary compound Homspera in treating the Hong Kong respiratory virus in mice. Additionally, company executives believe these test results are vital to research designed to develop a treatment for SARS.
The study, conducted at the University of Arizona Lung Injury Lab by Dr. Mark Witten, PhD, co-founder and acting head researcher of ImmuneRegen, was performed on 31 mice total. The results show that, of those mice treated with Homspera, over 90 percent survived the lung injury and currently do not appear to show any adverse signs or side effects from the exposure or the treatment.
Witten has over 20 years of experience in the research field and over 200 peer-reviewed scientific publications. His first research initiatives examined the role of lung permeability changes in the lungs after exposure to acute cigarette smoke. With funding obtained from the U.S. Army Medical Research & Materiel Command, Witten began to develop an acute smoke exposure model utilizing diesel fuel smoke. He spent two years as an instructor of medicine at Harvard Medical School, where he conducted additional research in Acute Respiratory Distress Syndrome (ARDS)/Acute Lung Injury (ALI). In 1990, he became Research Assistant Professor in the Department of Pediatrics at the University of Arizona College of Medicine, where he started his JP-8 inhalation toxicology research for the U.S. Air Force Office of Scientific Research.
Source: ImmuneRegen BioSciences, Inc.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.